8-Bromo-3-Methylxanthine CAS 93703-24-3 Linagliptin Intermediate Purity ≥99.0% Factory

Short Description:

Chemical Name: 8-Bromo-3-Methylxanthine

CAS: 93703-24-3

Purity: ≥99.0%

Appearance: White to Light Yellow Powder

Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment type II diabetes mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Linagliptin and Related Intermediates:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4
2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Chemical Name	8-Bromo-3-Methylxanthine
Synonyms	8-Bromo-3-Methyl-3,7-dihydro-1H-purine-2,6-dione
CAS Number	93703-24-3
CAT Number	RF-PI501
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C6H5BrN4O2
Molecular Weight	245.03
Melting Point	300℃(lit.)
Density	1.974g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Light Yellow Powder
Purity	≥99.0%
Loss on Drying	≤0.50%
Residue on Ignition	≤0.50%
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Heavy Metals	≤20ppm
Test Standard	Enterprise Standard
Usage	Intermediate for Linagliptin (CAS: 668270-12-0)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

8-Bromo-3-Methylxanthine (CAS: 93703-24-3) is a substituted derivative of of Xanthine. It can be used for the synthesis of Linagliptin (CAS: 668270-12-0), which is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes. It was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.Originator is Boehringer Ingelheim (United States).